HyperCVAD plus Imatinib or Dasatinib in Lymphoid Blastic Phase Chronic Myeloid Leukemia

BACKGROUND: Chronic Myeloid Leukemia (CML) may progress to blast phase (BP) at the rate of 1–1.5% per year. With the use of single-agent tyrosine kinase inhibitors (TKI), median overall survival (OS) ranges between 7 and 11 months. METHODS: We analyzed the outcome of 42 patients with lymphoid BP-CML...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Strati, Paolo, Kantarjian, Hagop, Thomas, Deborah, O’Brien, Susan, Konoplev, Sergej, Jorgensen, Jeffrey L, Luthra, Raja, Abruzzo, Lynne, Jabbour, Elias, Quintas-Cardama, Alfonso, Borthakur, Gautam, Faderl, Stefan, Ravandi, Farhad, Cortes, Jorge
Format: Artigo
Sprog:Inglês
Udgivet: 2013
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3946911/
https://ncbi.nlm.nih.gov/pubmed/24151050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28433
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker